J&J sues Mylan over Zytiga patent; NICE cracks down on antibiotics overuse; Kythera submits double-chin med for EU approval;

@FiercePharma: ICYMI yesterday: Will docs jump on new biosims? Survey shows they'll need some nudging. More | Follow @FiercePharma

@EricPFierce: Xellia decides it's best to have U.S. sales operations next to Raleigh, NC, plant it's expanding. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Mylan hopes Disney can add new magic to its allergy-fighting kingdom. FiercePharmaMarketing story | Follow @CarlyHFierce

> Generics-maker Mylan ($MYL) confirmed that it had been sued by Johnson & Johnson's ($JNJ) Janssen unit for patent infringement, over its branded cancer drug Zytiga. Release

> The National Institute for Health and Care Excellence (NICE) issued new guidelines designed to crack down on overuse of antibiotics to combat resistance to the meds. Report

> Kythera Biopharmaceuticals, which is about to be acquired by Allergan ($AGN), asked European regulators to approve its double-chin injection, approved in the U.S. as Kybella. Release

> AMAG Pharmaceuticals ($AMAG) wrapped up its $700 million buyout of Cord Blood Registry. Release

Medical Device News

@FierceMedDev: UPDATED with comment from Fujifilm: FDA slaps three duodenoscope manufacturers with warning letters. Article | Follow @FierceMedDev

@EmilyWFierce: San Diego's Genalyte reeled in $44M in a Series C round for its microchip testing platform. Release | Follow @EmilyWFierce

> WSJ: New devices for rectal cancer surgery reduce need for colostomies. Story

> Illumina, LabCorp, Mayo Clinic, Warburg assemble to back latest consumer genomics entrant: Helix. Article

> FDA slaps three duodenoscope manufacturers with warning letters over related devices. Report

Biotech News

@FierceBiotech: ICYMI: Kite CEO Arie Belldegrun has a simple message for investors this morning: Relax. Story | Follow @FierceBiotech

@JohnCFierce: No surprise, coming off a $70M crossover, RegenX Bio files $100M. S-1/Report | Follow @JohnCFierce

> Omeros soars on fresh promise for its rare disease treatment. More

> Wave LifeSci banks $66M with a 'pure' take on synthetic chemistry. Story

> Edge Therapeutics swings for a $115M IPO with eyes on Phase III. Article

> Esperion surges after FDA offers a shot at quick approval for LDL-lowering drug. Report

Drug Delivery News

> BioDelivery snags new FDA approval for Onsolis after ditching Meda partnership. More

> Hydrogels: Study shows use in ulcerative colitis and Army invests in wound healing research. Report

> Checkmate Pharma gets $20M in Series A to develop cancer candidate with VLP platform. Story

> Cannabics Pharma's extended-release medical marijuana capsules available in Colorado. Item

> Intersect's steroid-releasing implant meets its endpoint in bid for expanded indication. Article

Pharma Manufacturing News

> FDA castigates three Mylan sterile drug plants in warning letter. News

> Hemispherx says plant upgrade will allow it to return its genital wart treatment to market. Item

> GSK resumes production at plant where Legionella bacteria was detected. Report

> Merck manufacturing shedding another 2,600 jobs. Story

> Novo Nordisk looks at building its first U.S. insulin plant. Article

Pharma Asia News

> More scrutiny for Japanese duodenoscope makers on notification failures. Report

> India's Lee Pharma turned down on CL challenge to AZ's Onglyza. Item

> Does China yuan devaluation mean more downbeat pharma earnings? Article

> Japan's Mitsui buys stake in India top drug wholesaler Keimed. Story

> Going private for WuXi PharmaTech opens dealmaking options. More

And Finally... After recalling all its frozen desserts amid a deadly listeria outbreak, Blue Bell Creamery says it's ready to start selling ice cream again. Report

Suggested Articles

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.